Web• More than 20 years of experience in business management & revenue growth, working in the technology space across several fast growing industries. Proven track records of creating significant impacts in both global MNCs as well as startup environments. Ex … WebRay Ong is the Vice President, Commercial Operations at MiRXES where he drives the overall strategy for business development and sales of MiRXES’s products and services. Before joining MiRXES, Ray was the Oncology Business Development Manager at ThermoFisher … GASTROClear for Professionals GASTROClear GASTROClear is the … Discovery Solutions Exceptional miRNA detection powered by the class-leading … Cancer Screening Accurate, Actionable, and Affordable GASTROClear for Gastric … MiRXES MAGec RNA Extraction Kits use guanidine-based lysis and magnetic bead … The MiRXES Fortitude SARS-CoV-2 & FluA/B Test is intended for use by qualified and … ABOUT From Singapore for the world Our Purpose We deliver early, actionable and … NEWSROOM Stay current with MiRXES Featured Media Releases Keep up to … Cross-platform evaluation study led by Merck (MSD) scientists showing that …
MiRXES launches world’s first research project for a multi-cancer ...
[email protected]. Dr Ong is an Associate Professor and Associate Head (Research) in the Department of Civil and Environmental Engineering at the National University of Singapore (NUS). He graduated with a B.Eng (Civil) (First Class Honours) with a minor in Business from the National University of Singapore in 2003 and obtained his PhD in ... WebDr. Ray Ong Vice President, Commercial Operations MiRXES Singapore Professor Katherine Tuttle University of Washington Professor Alta Schutte University of New South Wales Sydney Professor Dr. Feng J He Wo fson Institute of Preventive Medicine, London HR2Z-m … sts 121 launch
MiRXES Pte Ltd
Web2014. Type: Company - Private. Industry: Biotech & Pharmaceuticals. Revenue: Unknown / Non-Applicable. Competitors: Unknown. MiRXES Pte Ltd is a Singapore headquartered biotechnology company with sales globally. MiRXES develops cutting-edge miRNA assay technologies and products for research and clinical diagnostic use. WebDrs Zhou Lihan, Zou Ruiyang and Too Heng-Phon discovered a way of detecting with unparalleled sensitivity the smallest strands of genetic material in the bloodstream known as microribonucleic acid WebJun 27, 2024 · Mirxes Pte, a Singapore-based biotechnology startup, is weighing an initial public offering in the city-state next year that could raise about US$300 million ($415.7 million), according to people with knowledge of the matter. The company is in discussions with bankers about a potential offering that could value it at over US$1 billion, said the ... sts 2023 abstract submission